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intracellular oxidants in airway
epithelium by allergen Der p 1To the Editor:
Group 1 cysteine protease allergens from house dust mites
(HDMs) are targets of a new class of drugs known as allergen
delivery inhibitors (ADIs), which are entering development for 2016 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).asthma therapy.1 In studying pro-inflammatory signaling by pro-
tease allergens, attention has focused on their direct cleavage of
protease-activated receptors (PARs).2 We have explored an alter-
native view, namely, that a key HDM allergen triggers the activa-
tion of thrombin and stimulates the production of intracellular
reactive oxygen species (ROS) and the extracellular release of
ATP. ROS have significance because they orchestrate an allergic
polarization of immune responses, and both heightened ROS pro-
duction and a broad deficit in antioxidant defenses are character-
istics of asthma.3
To investigate the production of intracellular ROS we loaded
human airway epithelial cells (primary cultures and established
lines) with dihydrorhodamine 123 and exposed them to a natural
mixture of Dermatophagoides pteronyssinus allergens. This re-
sulted in a sustained generation of ROS (Fig 1, A and B) associ-
ated with mitochondria and nuclei (Fig 1, C and D; see the
Methods section and Fig E1, A-D, in this article’s Online Repos-
itory at www.jacionline.org).
ADZ 51,457 and ADZ 51,529, which are reversible ADIs
targeting group 1 HDM protease allergens,1 substantially reduced
ROS generation (Fig 1, E). Purified natural Der p 1 replicated
ROS production and was fully inhibited by ADZ 51,457 (Fig 1,
F). In contrast, an irreversible inhibitor of serine proteases had
no effect on ROS production and purified Der p 2 conspicuously
failed to elicit ROS generation (see Fig E2, A and B, in this arti-
cle’s Online Repository at www.jacionline.org). Thus, among nat-
ural HDM allergens, the initiators of intracellular ROS generation
are the group 1 cysteine proteases.
Surprisingly, ROS production by HDM allergens was trans-
duced through PAR1 and PAR4, with only a small contribution
from PAR2 (Fig 1, G and H; see Fig E3, A-E, in this article’s On-
line Repository at www.jacionline.org). These responses required
the opening of pannexons, which are inter alia conduits for ATP
release (Fig 1, I). Interestingly, the viral RNA surrogate polyino-
sinic:polycytidylic acid (poly i:c) also caused pannexon-
dependent ROS production (Fig 1, I). Although HDM allergens
and poly i:c initiated ROS production differently (see Fig E4, A
and B, in this article’s Online Repository at www.jacionline.
org), their signaling converges at pannexons (Fig 1, I), with the
extracellular release of ATP and activation of mechanisms sensi-
tive to the allosteric P2X7 receptor modulator, AZ 10606120 (Fig
2, A and B).
Stimulation of PAR1 and PAR4 has not previously been
associated with Der p 1,2 so we were interested in determining
whether this involved the generation of thrombin, their canonical
activator. The thrombin inhibitor argatroban inhibited ROS gener-
ation by HDM allergens, whereas the Factor Xa inhibitor apixa-
ban was without effect (Fig 2, C and D; see Fig E5, A-C, in this
article’s Online Repository at www.jacionline.org), thus
excluding thrombin formation by the full coagulation cascade.
Interestingly, both argatroban and a PAR1 antagonist were effec-
tive inhibitors of poly i:c (Fig 2, E and F).
Incubation of prothrombin with mixed HDM allergens caused
the appearance of prethrombin-1, the zymogen form of meizo-
thrombin desF1, and the B chain of thrombin as major products.
This process was inhibited by ADZ 50,000, an irreversible active
site titrant analogue of ADZ 51,457 and ADZ 51,5291 (Fig 2, G).
Formation of thrombin by Der p 1 provides further insight into the
PAR siRNA data (Fig 1, G and H) and a possible explanation of
the extensive antagonism of ROS formation by PAR1 antagonists
(SCH 79797, FR 171113) and the PAR4 antagonist, tcY-NH2
FIG 1. A andB,ROSproduction in calu-3 cells and primary cultures of humanbronchial epithelial cells, respec-
tively, following vehicle (veh) or HDM allergen treatment (*P < .001 vs veh control). C and D, MitoSOX red/
NucBlue staining of calu-3 cells following veh or HDM1. E, Attenuation of HDM-induced ROS production by
Der p 1 inhibitors (*P < .001 vs veh control; **P < .001 vs HDM). F, Inhibition of Der p 1 by ADZ 51,457
(*P < .001 vs veh control; **P < .001 vs corresponding Der p 1 concentration). G and H, Inhibition of HDM
allergen-induced ROS production by the PAR1 antagonist SCH 79797 or by siRNA knockdown (*P < .001 vs
veh; **P < .001 vs HDM 1 with or without control [con] transfection). I, ROS production by HDM allergens or
by poly i:c is reduced in cells following knockdown of pannexin 1 (*P < .001 vs veh; **P < .001 vs HDM 1
with orwithout control transfection; P< .05 vspoly i:c; P< .001 vspoly i:cwithorwithout control transfection
NHBE, Normal human bronchial epithelial cells; RFU, relative fluorescence units.
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FIG 2. A and B, AZ 10606120 inhibits ROS production by HDM allergens or poly i:c (*P < .001 vs veh;
**P < .001 vs HDM or poly i:c, respectively). C and D, Argatroban inhibits ROS generation by HDM allergens
and by poly i:c (*P < .001 vs veh; **P < .001 vs HDM or poly i:c. F, Antagonism of poly i:c-dependent ROS
production by PAR1 antagonist FR 171113 (P < .001 except at 3 mM). G, Time-dependent proteolysis of pro-
thrombin 1 by mixed HDM allergens and its inhibition by ADZ 50,000. NHBE, Normal human bronchial
epithelial cells; RFU, relative fluorescence units.
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cedented, providing a mechanism for thrombin bound to PAR1
through exosite 1 to cleave PAR4 (which cannot bind) more effi-
ciently.4 The formation of a ternary complex would thus render
ROS generation sensitive to antagonism of both receptors and
imply that the main effector of Der p 1–stimulated ROS produc-
tion might be PAR4, which is notably associated with epithelial-
mesenchymal transition in airway cells.
Hitherto, PAR1 and PAR4 have not been considered activatable
by group 1 HDM allergens,2 but in revealing the Der p 1–depen-
dent cleavage of prothrombin we have identified their canonical
activation with subsequent intracellular ROS formation via ATP
release. Extracellular ATP is elevated in asthma, which is note-
worthy because it stimulates dendritic cells and triggers the
release of IL-33, which is genetically linked to asthma suscepti-
bility and a key activator of cytokine production by iH2 nuocytes.
5
Thrombin is present in airway surface liquid in asthma at levels
sufficiently elevated to drive cell proliferation and is also
increased following respiratory virus infection.6 Although it is
generally assumed that these changes are associated with tissue
repair following inflammation, our data implicate thrombin-
mediated signaling as both an innate strategic initiator and an
effector-perpetuator of allergic sensitization through its direct
generation by inhaled Der p 1.
That the Toll-like receptor 3 ligand poly i:c operates ROS
generation through a mechanism that converges with Der p 1
signaling at pannexons is interesting because interactions be-
tween allergens and respiratory viruses precipitate exacerbations
of asthma and allergy-polarizing transcription factors are redox
sensitive. PAR1 contributes to the pathogenicity of influenza A,7
PAR1 and Toll-like receptor 3 are both upregulated by respiratory
virus infections,8 ATP promotes TH2 immunity, and P2X7 expres-
sion is upregulated in asthma.5 It will therefore be of interest to
investigate the operational role of pannexons as a signaling nexus
in allergic sensitization and the triggering of disease
exacerbations.
The sensitivity of Toll-like receptor 3–mediated activation to
argatroban or PAR1 antagonists (see Fig E2, E-F) suggests that
events downstream of pannexon opening involve the endogenous
activation of thrombin, creating a cyclical process. These findings
reveal a surprising primary trigger for thrombin production that
further emphasize its contribution to inflammatory lung re-
sponses. Although an oral thrombin inhibitor, albeit with
bioavailability and protein binding which may preclude signifi-
cant airway access from the systemic circulation, has only mod-
erate improving effect on HDM-induced pathology in a murine
model,9 our data suggest that it would be of interest to explore
similar effects of ADIs, especially as these molecules have been
optimized with the pharmaceutical credentials for inhaled
delivery.
Additional information is available (see this article’s Methods,
Results, and References sections in the Online Repository at
www.jacionline.org).
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tifies micro-RNA–based biomarker
panel for Kawasaki diseaseTo the Editor:
Kawasaki disease (KD) is an autoimmune disease preferen-
tially attacking children younger than 5 years. Symptoms of KD
include fever for at least 5 days, oral mucosal inflammation,
nonsupportive conjunctivitis, lymphadenopathy, edema of the
extremities, and a polymorphous rash. If left untreated, almost
20% to 25% of the patients with KDmay develop severe coronary
artery aneurysms, making KD the leading cause of acquired
heart disease in young children in developed countries.1 The
successful detection of KD within the first 10 days of fever onset
followed by treatment with high-dose intravenous immuno-
globulin can greatly reduce the risk of severe coronary artery
lesions.1-3 Therefore, early and successful detection is critical
for treating KD.
